Thanks to the hemato-encephalic barrier the CNS compartment is not exposed to effective plasma levels of standard front-line anti-lymphoma regimen (e.g., R-CHOP), thereby enabling lymphoma cell survival with no need for large-scale genomic, transcriptional, or post-translational changes. Here, DDIT3 is linked to lymphoma.